Merck & Co.

Gilead's Sovaldi patent under fire again from MSF coalition, this time in Europe

Eli Lilly says it's cutting an average of 50% off list prices—and its price hikes don't work

I-O latecomers Pfizer and Merck KGaA fall further behind rivals with new lung cancer delays